Remote magnetic navigation for mapping and ablation of right and left ventricular outflow tract arrhythmias

Leonor Parreira*, Diogo Cavaco, Katya Reis-Santos, Pedro Carmo, David Cabrita, Mauricio Scanavacca, Pedro Adragão

Centro do Ritmo Cardíaco, Hospital da Luz, Lisboa, Portugal

Received 3 May 2012; accepted 7 December 2012
Available online 12 July 2013

Abstract

Objective: The aim of this study was to assess the efficacy and potential complications of a remote-controlled magnetic navigation system (Niobe II, Stereotaxis) for mapping and ablation of right or left ventricular outflow tract ventricular tachycardia or premature ventricular contractions.

Methods: We studied 32 consecutive patients, mean age 43 ± 11 years, 24 female. Mapping of the arrhythmia was performed using the CARTO RMT mapping system, remotely guided by the Niobe II. Radiofrequency ablation was performed at the site of earliest ventricular activation with pacemapping of at least 11/12 leads.

Acute success was defined as suppression and non-inducibility of the arrhythmia after stimulation with isoprenaline. After a minimum 3-month follow-up, we assessed clinical success (absence of symptoms and suppression of the arrhythmia on Holter recording), defined as less than 50 premature ventricular contractions/24 hours.

Results: The origin of the arrhythmia was in the right ventricular outflow tract in 28 patients (88%), in the left in three, and in the epicardium in one. Acute success was achieved in 26 patients (81%). Two patients underwent a second successful procedure, in one of which an epicardial approach was necessary. The overall clinical success rate, after two repeat procedures, was 88%. No complications occurred.

There were two recurrences during a mean follow-up of 307 ± 204 days.

Conclusion: The Niobe II remote control system for mapping and ablation of ventricular outflow tract arrhythmias is effective and safe, and provides precise mapping and a high success rate, with no complications.

© 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.

*Corresponding author.
E-mail addresses: lparreira@netvisao.pt, leonor.parreira@gmail.com (L. Parreira).
PALAVRAS-CHAVE
Taquicardia ventricular; Extrassístoles ventriculares; Ablação por radiofrequência; Navegação magnética; Estereotaxia

Ablação de arritmias da câmara de saída do ventrículo direito e esquerdo com sistema de navegação magnética por controlo remoto

Resumo
Objetivos: Avaliar a eficácia e segurança do sistema de navegação magnética por controlo remoto Niobe II (Stereotaxis) na ablação de taquicardia ventricular ou extrassístoles ventriculares da câmara de saída do ventrículo direito e esquerdo.
Métodos: Estudaram-se 32 doentes consecutivos, idade média 43±11 anos, 24 mulheres referenciados para ablação. O mapeamento da arritmia foi efetuado com o sistema CARTO RMT, orientado por controlo remoto. A ablação foi realizada com radiofrequência no local de ativação mais precoce com pacemapping de pelo menos 11/12. O sucesso foi definido como a supressão da arritmia e a sua não inducibilidade sob isoprenalina.
Após um seguimento mínimo de 3 meses avaliámos o sucesso clínico, definido como a ausência de sintomas e a supressão de arritmias no Holter, definido como < 50 extrassístoles ventriculares/24 h.

Resultados: Em 28 doentes, a arritmia originava-se na câmara de saída do ventrículo direito (88%), em 3 no esquerdo, e noutro no epicárdio. O sucesso agudo foi obtido em 26 doentes (81%). Dois doentes efetuaram um segundo procedimento com sucesso, um deles por abordagem epicárdica. O sucesso final, após 2 procedimentos em 2 doentes, foi de 88%. Não ocorreram complicações. Durante um período de seguimento de 307±204 d, ocorreram 2 recorrências.
Conclusões: O sistema de navegação magnética por controlo remoto mostrou-se eficaz e seguro para mapeamento e ablação de arritmias das câmaras de saída ventricular, permitindo um mapeamento preciso com uma elevada taxa de sucesso e sem complicações.

© 2012 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os direitos reservados.

INTRODUÇÃO

Taquicardia ventricular (VT) e extrassístoles ventriculares (PVCs) da câmara de saída do ventrículo direito ou esquerdo são arritmias comuns, ocorrendo em cerca de 10% de todos os arritmias ventriculares.1

A natureza focal destas arritmias torna a ablação um tratamento eficaz, com taxas de sucesso entre 81% e 100%.2,3

O procedimento de mapeamento tradicional é uma tarefa complexa e desafiadora, exige uma manipulação cuidadosa e um alto grau de exatidão.4,5

A finalidade deste estudo foi avaliar a eficácia e segurança do sistema de mapeamento magnético para ablação de arritmias de origem na câmara de saída do ventrículo direito ou esquerdo, em um grupo maior de pacientes e com um período de seguimento mais longo.

MÉTODOS

Seleção de pacientes

Entre julho de 2008 e junho de 2011, 32 pacientes consecutivos foram submetidos a procedimentos de mapeamento e ablação de taquicardia ventricular ou extrassístoles de origem nos ventrículos direito e esquerdo.

Ninguém foi excluído para o procedimento, e todos assinaram o termo de consentimento.

Estudo eletrofisiológico

Os pacientes foram avaliados seis horas após a última refeição e sem sedação. Todas as medicações antiarritmicas foram interrompidas pelo menos 5 halflives antes do estudo eletrofisiológico; nenhum paciente estava a tomar amiodarona.

Tecnologia magnética

Dois sistemas de mapeamento magnético têm sido desenvolvidos para facilitar a manipulação dos cateteres e reduzir a exposição à radiação: o sistema Niobe II (Stereotaxis) e o sistema Sensei (Hansen) que usa um robô de manipulação remoto.

Considerando os resultados iniciais de ambos os sistemas, com taxas de sucesso entre 80% e 100%, parece indicado que o sistema de mapeamento magnético seja uma opção segura e eficaz para o tratamento de arritmias da câmara de saída do ventrículo direito ou esquerdo.
Surface electrocardiograms and intracavitary electrograms were recorded on an AXIOM Sensis system (Siemens Systems). Programmed stimulation was performed using a UHS 3000 heart stimulator (Biotronik). The catheters were inserted via the femoral vein and positioned under fluoroscopic guidance in the His bundle and in the great cardiac vein via the coronary sinus. Isoprenaline infusion was titrated until induction of VT/PVCs. The protocol included ventricular stimulation in the apex and RVOT with a basic cycle of 600/500/400 ms and 54 until the refractory period was reached and continuous ventricular and atrial stimulation.

Magnetic navigation

All procedures were performed using an AXIOM Artis (Siemens) fluoroscopic imaging system.

The MNS has been previously described; it basically consists of two computer-controlled magnets positioned on either side of the fluoroscopy table, which create a magnetic field (0.1 T). The position of the magnets is controlled from a console, the Navigant workstation, which orients the magnetic field according to vectors selected by the operator. The ablation catheter has three magnets at its distal end, which orientate it parallel to the magnetic field. Changes in the orientation of the magnetic field deflect the catheter, which is advanced remotely by a motor at the proximal end of the catheter (Cardiodrive, Stereotaxis). Magnetic field vectors can be stored, enabling subsequent automatic navigation to previous sites.

Mapping and ablation

The MNS is integrated with a CARTO XP RMT (Biosense Webster) electroanatomical mapping system and receives real-time information on the position and orientation of the mapping catheter tip.

This information is overlaid on the fluoroscopic images on the Navigant workstation, providing real-time monitoring of the catheter position without the need for further fluoroscopy (Figure 1).

Mapping was performed during VT or in sinus rhythm for those with PVCs. A 4-mm Navistar RMT (Biosense Webster) catheter with three magnets at its tip was used until the Navistar RMT Thermocool (Biosense Webster) magnetic irrigated catheter became available, which was then used in all subsequent procedures. The ablation catheter was introduced via the femoral vein and advanced manually to the right atrium, and then remotely to the His bundle and the RVOT. The locations of the His bundle and the pulmonary valve were marked.

Detailed mapping of ventricular activation was performed in patients in sinus rhythm with PVCs and in those in VT.

Bipolar activation times were reviewed manually and activation maps were generated in automatic mode, the earliest isochrone being considered the EAS. Following isochronal reconstructions of the RVOT and LVOT, pacemapping was performed in multiple endocardial sites close to the EAS. Ventricular stimulation for pacemapping was performed with the same cycle as that of VT or with the coupling interval of the PVCs. Radiofrequency energy (RF) was applied at the EAS showing a QS pattern on the unipolar signal and pacemapping with 11/12 or 12/12 lead match. When mapping of the RVOT did not identify a site meeting these criteria, the LVOT was mapped by introducing the ablation catheter into the left ventricle using a retrograde approach via the femoral artery, with administration of intravenous heparin after arterial puncture.

Using an EP Shuttle RF generator (Stockert), RF was applied between the distal electrode of the ablation catheter and a cutaneous patch electrode for up to 120 s, with a power limit of 55 W and maximum temperature of 55 °C in the case of the 4-mm catheter, and power limit of 35 W and maximum temperature of 43 °C with the irrigated catheter. When this was ineffective, additional RF applications were performed at sites adjacent to the EAS with good pacemapping. Light sedation with midazolam (bolus) or remifentanil (perfusion) was administered during RF application when necessary.

Procedure and fluoroscopy times were recorded, as well as the number and duration of RF applications. Procedure time was defined as the interval between venous puncture and removal of the introducer.

Success was defined as suppression of PVCs or non-inducibility of VT following stimulation with isoprenaline up to 30 min after ablation.

All patients remained under surveillance in hospital for 24 hours after the procedure.

Follow-up

Follow-up consultations included clinical assessment and 24-h Holter monitoring in the first month, at three months and every six months thereafter.

Clinical success was defined as absence of symptoms and suppression of arrhythmias on Holter monitoring (<50 PVCs/24 h).

Statistical analysis

Data are presented as means ± standard deviation for continuous variables and as frequencies for discrete variables.

Results

Population

Thirty-two patients, mean age 43±11 years, 24 female, underwent ablation of VT or frequent PVCs.

Six had documented VT, while 26 presented frequent PVCs on 24-h Holter monitoring (minimum of 10 000/24 h) that were symptomatic and refractory to therapy. All patients underwent echocardiographic study, on which none presented left or right ventricular morphological changes. Four patients had hypertension. Sustained VT could not be induced in four of the six patients with documented VT, while well-tolerated VT, with cycles of 388 ms and 400 ms, was induced in two with isoprenaline perfusion.
Figure 1  Reference fluoroscopic images on the Navigant workstation in right and left anterior oblique views showing the position of the ablation catheter (blue star) in real time without need for further fluoroscopy; MNS automatic vector indicating the right ventricular outflow tract (yellow vector) and the His bundle (yellow dots).

Mapping and ablation

The RVOT was identified as the origin of the arrhythmia in 28 patients, septal in 20 and in the free wall in eight. The arrhythmia originated in the left ventricle in three patients, one in the right coronary cusp and two in the LVOT. Mapping of the right and left ventricles in one patient failed to identify a sufficiently early activation site, and an epicardial origin was assumed.

Mapping was performed during VT in two patients, and in sinus rhythm in those with PVCs. At the ablation site, the ventricular electrogram preceded the start of the QRS complex by at least 30 ms, with pacemapping of 11/12 or 12/12 leads.

In the three patients with left ventricular arrhythmias, coronary angiography was performed prior to ablation. Remote magnetic navigation was used to map the RVOT and LVOT in all procedures; a 4-mm catheter was used in the first three procedures and an irrigated catheter in the other 31.

During the first seconds of RF application at sites of successful ablation, VT runs of similar morphology to the clinical arrhythmia occurred, and when ablation during VT was performed, the arrhythmia was suppressed during application. Ablation was successful in 26 patients (81%), and was unsuccessful in six; in one patient the EAS was less than 5 mm from the right coronary ostium (Figure 2), and the origin of the arrhythmia was assumed to be epicardial in another.

Two patients underwent repeat procedures. A transpericardial approach was used in the patient with an epicardial focus; an irrigated ablation catheter was introduced into the pericardial space through a long sheath and epicardial mapping was performed using the MNS. The EAS was identified in the anterior side of the LVOT next to the anterior interventricular vein. The epicardial electrogram at the ablation site preceded the QRS complex by 42 ms with pacemapping of 12/12 leads; following coronary angiography, RF ablation at this site suppressed the EAS (Figure 3). The other patient, with the EAS in the RVOT, underwent successful repeat ablation 11 months after the first procedure. The overall success rate, after repeat procedures in two patients, was 88%. Mean procedure time was 208±79 min and mean fluoroscopy time was 10±7.8 min. An average of 9±7 applications per patient were performed, with a mean RF application time of 460±290 s.
Follow-up

No complications related to remote mapping or ablation were observed. During a mean follow-up of 307±204 days, two patients presented recurrent PVCs on Holter monitoring, one of whom was asymptomatic and PVCs decreased from 24 000/24 h before ablation to 5000/24 h after ablation; the other reported symptoms but refused a repeat procedure.

Discussion

Conventional ablation catheters have to negotiate two curves to reach the RVOT, the first between the right atrium and the RVOT and the second between the inflow tract and the outflow tract, which makes manipulation difficult and hinders rapid and accurate mapping.

The Niobe II MNS enables the ablation catheter to negotiate various curves within the cardiac chambers, and the
tip can be steered in any direction, thus providing ease and precision of mapping unobtainable with conventional catheters. The MNS, the ablation catheter can easily be positioned at any site in the RVOT or LVOT without the need for long sheaths, enhancing catheter stability, as previously demonstrated.

The options for automatic mapping (AutoMap) on the Navigation workstation, together with the possibility of returning to previously mapped sites using stored magnetic field vectors without fluoroscopic guidance, reduce overall fluoroscopy times. The mean fluoroscopy time with this method of $10 \pm 7.8$ min is much shorter than in other studies with conventional ablation using three-dimensional mapping systems ($45.9 \pm 17.9$ min) or multielectrode mapping catheters ($49.7 \pm 26.3$ min).

Manipulation of catheters in structures like the LVOT and RVOT carries a risk of perforation. The flexibility of the MNS catheter, together with its soft tip, reduces the force applied to the endocardium compared to conventional catheters, which may explain the absence of complications in this and other studies.

Limitations

The present study was not randomized and included a small number of patients, and no comparison was made with conventional ablation in terms of procedure or fluoroscopy times or efficacy.

Conclusion

The remote control Niobe II system for mapping and ablation of arrhythmias originating in the ventricular outflow tracts was effective and safe in our patient group, with reduced fluoroscopy times and no complications.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Europace. 2009;11:771–817.


Remote magnetic navigation for mapping and ablation of right and left ventricular outflow tract arrhythmias

